Imaging and biodistribution of radiolabeled SP90 peptide in BT-483 tumor bearing mice

Copyright © 2020 Elsevier Ltd. All rights reserved..

The objective of this study was to evaluate radiolabeled DOTA-SP90 as a radiotracer for breast cancer. The in vitro competition assay showed that radiolabeled DOTA-SP90 had significant binding affinity to BT-483 cancer cells. Biodistribution, nanoSPECT/CT and nanoPET/CT imaging results indicated that radiolabeled DOTA-SP90 can accumulate in tumors. In addition, radiolabeled DOTA-SP90 peptides can also detect metastatic tumors. Therefore, radiolabeled SP90 peptide may provide the potential capability as diagnostic agent for breast cancer patients.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:161

Enthalten in:

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine - 161(2020) vom: 14. Juli, Seite 109162

Sprache:

Englisch

Beteiligte Personen:

Lo, Wei-Lin [VerfasserIn]
Liang, Chen-Hsien [VerfasserIn]
Chen, Liang-Cheng [VerfasserIn]
Lee, Shih-Ying [VerfasserIn]
Lo, Sheng-Nan [VerfasserIn]
Chen, Ming-Wei [VerfasserIn]
Lu, Ruei-Min [VerfasserIn]
Liu, I-Ju [VerfasserIn]
Wu, Han-Chung [VerfasserIn]
Chang, Chih-Hsien [VerfasserIn]

Links:

Volltext

Themen:

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1HTE449DGZ
BT-483
DOTA-SP90
Gallium Radioisotopes
Heterocyclic Compounds, 1-Ring
Indium Radioisotopes
Journal Article
NanoPET/CT
NanoSPECT/CT
Oligopeptides
Radiopharmaceuticals
SP90 peptide

Anmerkungen:

Date Completed 07.07.2021

Date Revised 07.07.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.apradiso.2020.109162

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM311397794